Retirement Systems of Alabama Reduces Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Retirement Systems of Alabama decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 380,379 shares of the biopharmaceutical company’s stock after selling 4,246 shares during the quarter. Retirement Systems of Alabama’s holdings in Halozyme Therapeutics were worth $19,787,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Isthmus Partners LLC raised its holdings in Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC raised its holdings in Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares in the last quarter. Xponance Inc. raised its holdings in Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after purchasing an additional 198 shares in the last quarter. Bessemer Group Inc. raised its holdings in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Halozyme Therapeutics by 4.0% in the first quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 215 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $50,648,622.57. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicole Labrosse sold 2,227 shares of Halozyme Therapeutics stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at $1,721,058.05. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a report on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, October 21st. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Hold” and a consensus target price of $73.11.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $65.19 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The business has a fifty day moving average price of $71.16 and a 200-day moving average price of $62.52. The company has a market capitalization of $7.63 billion, a PE ratio of 14.92, a PEG ratio of 0.35 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same period last year, the company earned $0.91 EPS. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.